Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 16.680-17.500 for the period, compared to the consensus estimate of 15.830. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.7 billion.

Medpace Trading Down 2.2%

MEDP opened at $530.35 on Tuesday. The company has a market cap of $14.94 billion, a P/E ratio of 37.09, a PEG ratio of 1.82 and a beta of 1.42. The company’s 50 day moving average is $578.30 and its 200-day moving average is $539.57. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts forecast that Medpace will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Barclays lifted their target price on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, BMO Capital Markets initiated coverage on Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Medpace presently has a consensus rating of “Reduce” and an average price target of $491.27.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares in the company, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 302,192 shares of company stock worth $182,019,762. 20.30% of the stock is owned by company insiders.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. bought a new position in Medpace in the 3rd quarter worth $283,000. Wilmington Savings Fund Society FSB grew its position in Medpace by 124.1% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock valued at $67,000 after purchasing an additional 72 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Medpace by 12.3% during the third quarter. Sunbelt Securities Inc. now owns 464 shares of the company’s stock valued at $239,000 after buying an additional 51 shares during the last quarter. Captrust Financial Advisors boosted its stake in Medpace by 9.9% during the 3rd quarter. Captrust Financial Advisors now owns 44,575 shares of the company’s stock valued at $22,919,000 after purchasing an additional 4,003 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Medpace during the third quarter valued at $1,347,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.